Daiichi Sankyo
Bookmark
ShareDaiichi Sankyo is a company. It is located in Tokyo, Japan and was founded in 2007. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Tokyo
- country: Japan
- employees: 16,458 people
- revenues: 7.4B $
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 2007
- CEO: Sunao Manabe
- CEO gender: male
- CEO approval: 86 %
- ESG score: 25.02 / 100
See more facts
Extract data
Download datasets about Daiichi Sankyo:
Stocks from Daiichi Sankyo:
Daiichi Sankyo is one of the companies in Sunao Manabe, companies in Japan, companies in Pharmaceuticals, companies in Health Care and 3,584,319 companies in our database.
Talking Points
- Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries ...
- Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Related
Connected or similar to Daiichi Sankyo: .
This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.
This content is available under the CC BY 4.0 license.
